Navigation Links
Studies suggest new brain protein may help in treating schizophrenia, insomnia and anxiety

A small protein in the brain that has only recently been discovered and, paradoxically, induces both profound wakefulness and a less anxious state, may represent a novel target for the treatment of psychotic behavior and schizophrenia, according to new research presented at the 6th International Congress of Neuroendocrinology (ICN 2006). ICN 2006 is being held at the David L. Lawrence Convention Center in Pittsburgh June 19 ?22.

Neuropeptide S (NPS), so named by Rainer K. Reinscheid, Ph.D., assistant professor, Program in Pharmaceutical Sciences, University of California, Irvine, is produced by a small cluster of cells in the brainstem, yet its specialized receptors are found in several areas of the brain, including those that are associated with the regulation of arousal, sleep and wakefulness, anxiety, appetite, learning and memory. Dr. Reinscheid and his colleagues reported finding the new neuropeptide just last year and described animal studies showing how binding of NPS to its receptors on the surfaces of neurons promotes strong arousal, suppresses all phases of sleep and lessens anxiety in stressful or unfamiliar situations.

Now, at ICN 2006, Dr. Reinscheid's group reports how NPS also can reduce the biochemical and behavioral symptoms of schizophrenia in an established animal model for this mental illness that affects some 2 million Americans. Animals pretreated with NPS before receiving a drug that normally induces psychotic-like behaviors did not develop the signature behavioral symptoms and neurochemical features of schizophrenia, reported Naoe Okamura, M.D., Ph.D., who is a co-worker of Dr. Reinscheid at the University of California, Irvine.

"Although preliminary, our animal studies indicate the NPS receptor should be explored as a target for the development of novel antipsychotic drugs. Whether molecules activating the NPS system will prove to be better drugs than others used to treat the symptoms of schizophrenia remains to be seen. We still have a very long way to go before proving it can alleviate symptoms in humans as we've seen it do in rodents," said Dr. Reinscheid.

"We've already seen how NPS is unique, being able to modulate both arousal and stress responses. So it could potentially be a target for drugs to treat anxiety and, interestingly, both insomnia and narcolepsy," he added.

The receptor for NPS belongs to a class of those with similar structure called G protein-coupled receptors. Collectively, they have a hand in modulating most every physiological process in the body and brain. Moreover, according to Dr. Reinscheid, about 40 percent of drugs on the market target the function and various actions of these receptors.

Dr. Reinscheid's lab is only beginning to understand how the NPS system works. Thus far, the team's research suggests it acts much like an excitatory neurotransmitter that initiates an impulse by the receiving neuron. Currently, the team is looking at whether natural mutations in the genes of NPS and its receptor might be associated with mental disorders and developing animal models that lack parts of the NPS system in order to better understand its functions.


'"/>

Source:University of Pittsburgh Medical Center


Related biology news :

1. Studies reveal methods viruses use to sidestep immune system
2. Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine
3. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
4. Studies on human genome variation provide insight into disease
5. Studies find general mechanism of cellular aging
6. Studies look at how genes affect antipsychotic drug response
7. Studies yield insight into the numerical brain
8. Studies force new view on biology of flavonoids
9. New studies suggest airborne SARS transmission is possible
10. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
11. Light therapy may combat fungal infections, new evidence suggests
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/10/2019)... ... January 09, 2019 , ... Dr. Beanlands is the Vered Chair ... Ontario, Canada. He is also Director of its National Cardiac PET Centre, and ... Department of Radiology, and in the Department of Cellular and Molecular medicine. , He ...
(Date:1/10/2019)... N.J. (PRWEB) , ... January 10, 2019 , ... ... to improve the translational gap between inexpensive in vitro studies and significantly more ... prediction of in vivo efficacy and toxicity. To address this need, researchers have ...
(Date:1/8/2019)... HOUSTON (PRWEB) , ... January 07, 2019 , ... ... disposal and compliance solutions, is proud to welcome Thomas Kennedy as head of ... Jeffery Miglicco, CEO for PureWay. , Mr. Kennedy has previously worked for Johnson ...
Breaking Biology News(10 mins):
(Date:1/8/2019)... ... January 08, 2019 , ... The American Society of Gene and Cell ... a selection committee made up of industry leaders identified by the ASGCT board of ... mentored awards created to support ASGCT members designing transformative pilot studies in gene and ...
(Date:1/4/2019)... SAN DIEGO (PRWEB) , ... January 03, 2019 ... ... company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the ... Calidi Biotherapeutics to receive critical input and guidance from key leaders in the ...
(Date:12/18/2018)... ... December 18, 2018 , ... USDM Life ... the life sciences industry, unveiled a completely redesigned website at http://www.usdm.com . ... browsing experience for their valued clients and business partners. , The website ...
(Date:12/13/2018)... , ... December 12, 2018 , ... Helping conclude Healthy ... new sleek and slim hearing aid within its Vision and Hearing campaign that sets ... , Studies show that despite continued efforts to destigmatize hearing aids over the ...
Breaking Biology Technology: